PlainRecalls
FDA Drug Critical Class I Terminated

VITRAKVI (larotractenib) oral solution, 20mg/mL, 100 mL bottle, Rx only, Manufactured for Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981. NDC 50419-392-01

Reported: December 6, 2023 Initiated: November 6, 2023 #D-0145-2024

Product Description

VITRAKVI (larotractenib) oral solution, 20mg/mL, 100 mL bottle, Rx only, Manufactured for Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981. NDC 50419-392-01

Reason for Recall

Microbial Contamination of Non-Sterile Products: microbial contamination identified as Penicillium brevicompactum observed during routine ongoing stability testing

Details

Units Affected
192 bottles
Distribution
Product was distributed to specialty pharmacies and distributors nationwide who may have further distributed the product.
Location
Whippany, NJ

Frequently Asked Questions

What product was recalled?
VITRAKVI (larotractenib) oral solution, 20mg/mL, 100 mL bottle, Rx only, Manufactured for Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981. NDC 50419-392-01. Recalled by Bayer Healthcare Pharmaceuticals Inc.. Units affected: 192 bottles.
Why was this product recalled?
Microbial Contamination of Non-Sterile Products: microbial contamination identified as Penicillium brevicompactum observed during routine ongoing stability testing
Which agency issued this recall?
This recall was issued by the FDA Drug on December 6, 2023. Severity: Critical. Recall number: D-0145-2024.